For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $0.28 in the prior trading day, Viracta Therapeutics Inc (NASDAQ: VIRX) closed at $0.26, down -6.74%. In other words, the price has decreased by -$6.74 from its previous closing price. On the day, 0.68 million shares were traded. VIRX stock price reached its highest trading level at $0.29 during the session, while it also had its lowest trading level at $0.2555.
Ratios:
Our goal is to gain a better understanding of VIRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.08 and its Current Ratio is at 1.08. In the meantime, Its Debt-to-Equity ratio is 7.05 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on August 16, 2024, Downgraded its rating to Market Perform and sets its target price to $3 from $5 previously.
On February 01, 2022, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $10.
On May 03, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $35.H.C. Wainwright initiated its Buy rating on May 03, 2021, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 27 ’24 when Chevallard Daniel R. sold 3,405 shares for $0.73 per share. The transaction valued at 2,493 led to the insider holds 102,306 shares of the business.
Rothera Mark bought 52,094 shares of VIRX for $25,734 on Nov 30 ’23. The President and CEO now owns 52,094 shares after completing the transaction at $0.49 per share. On Dec 01 ’23, another insider, Rothera Mark, who serves as the President and CEO of the company, bought 47,906 shares for $0.49 each. As a result, the insider paid 23,627 and bolstered with 100,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIRX now has a Market Capitalization of 11266368 and an Enterprise Value of 4624832.
Stock Price History:
Over the past 52 weeks, VIRX has reached a high of $1.52, while it has fallen to a 52-week low of $0.27. The 50-Day Moving Average of the stock is -45.96%, while the 200-Day Moving Average is calculated to be -60.07%.
Shares Statistics:
The stock has traded on average 544.33K shares per day over the past 3-months and 2858480 shares per day over the last 10 days, according to various share statistics. A total of 39.09M shares are outstanding, with a floating share count of 27.71M. Insiders hold about 29.71% of the company’s shares, while institutions hold 21.80% stake in the company. Shares short for VIRX as of 1722384000 were 912026 with a Short Ratio of 1.68, compared to 1719532800 on 720975. Therefore, it implies a Short% of Shares Outstanding of 912026 and a Short% of Float of 2.96.
